James N. Topper
InvestorManaging Partner at Frazier Life Sciences · Board director at Seraxis · Board director at Aptinyx · Board director at Alpine Immune Sciences
Palo Alto
About
James (Jamie) Topper co-leads Frazier's Life Sciences team as a Managing Partner, having joined the firm in 2003 and opened its first California office. Over more than two decades there, he has led or co-led investments in over 60 therapeutics-focused companies. Before joining Frazier, he headed cardiovascular R&D at Millennium Pharmaceuticals and served as VP of Biology at COR Therapeutics, and previously held faculty positions at Stanford and Harvard Medical School. He earned an M.D. and Ph.D. in Biophysics from Stanford and a B.S. from the University of Michigan.
Contact· self-published, not guessed
Invests in
Biotech
Board director at Seraxis
Intro paths
In turn, James can intro founders to Seraxis's investors below.
Seraxis's investors · 4
Co-founders at Seraxis
Board director at Aptinyx
Intro paths
In turn, James can intro founders to Aptinyx's investors below.
Aptinyx's investors · 6
Co-founders at Aptinyx
Board director at Alpine Immune Sciences
Intro paths
In turn, James can intro founders to Alpine Immune Sciences's investors below.
Alpine Immune Sciences's investors · 3
Co-founders at Alpine Immune Sciences
Deals · 14
AtterocorBoard seat
via Frazier Life Sciences · filed Dec 2017 · $59.1M raise
AlcrestaBoard seat
via Frazier Life Sciences · filed Oct 2016 · $50.9M raise
AptinyxBoard seat
via Frazier Life Sciences · filed May 2016 · $65M raise
Merganser BiotechBoard seat
via Frazier Life Sciences · filed Apr 2016 · $17.1M raise
Allena PharmaceuticalsBoard seat
via Frazier Life Sciences · filed Dec 2015 · $53M raise
AnaptysBioBoard seat
via Frazier Life Sciences · filed Jul 2015 · $40.8M raise
ChanRxBoard seat
via Frazier Life Sciences · filed Feb 2015 · $31.9M raise
Alpine Immune SciencesLed round
AlnaraLed round
CoTherixLed round
InclineLed round
MavupharmaLed round
PortolaLed round
RempexLed round
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Led
Acerta Pharma BVCalistoga PharmaceuticalsThreshold
Board seats
Amunix Pharmaceuticals, Inc.Architect TherapeuticsAttovia TherapeuticsCounterakt TherapeuticsDiagonal TherapeuticsEnlaza TherapeuticsImmutrinNewAmsterdam PharmaPhathom Pharmaceuticals
Sources: the firm's website · SEC Form D filings.
Colleagues at Frazier Life Sciences
Frequently asked questions
- Who is James N. Topper?
- James (Jamie) Topper co-leads Frazier's Life Sciences team as a Managing Partner, having joined the firm in 2003 and opened its first California office. Over more than two decades there, he has led or co-led investments in over 60 therapeutics-focused companies. Before joining Frazier, he headed cardiovascular R&D at Millennium Pharmaceuticals and served as VP of Biology at COR Therapeutics, and previously held faculty positions at Stanford and Harvard Medical School. He earned an M.D. and Ph.D. in Biophysics from Stanford and a B.S. from the University of Michigan.
- Where does James N. Topper work?
- James N. Topper is Managing Partner at Frazier Life Sciences and Board director at Seraxis and Board director at Aptinyx and Board director at Alpine Immune Sciences.
- What does James N. Topper invest in?
- James N. Topper invests in Biotech.
- What boards does James N. Topper sit on?
- James N. Topper holds tracked board seats at Alcresta, Allena Pharmaceuticals, Amunix Pharmaceuticals, Inc., AnaptysBio, AnaptysBio, Aptinyx, Architect Therapeutics, Atterocor, Attovia Therapeutics, ChanRx.
- What companies has James N. Topper invested in?
- Investments tracked here include Acerta Pharma BV, Alnara, Alpine Immune Sciences, Calistoga Pharmaceuticals, CoTherix, Incline, Mavupharma, Portola, Rempex, Threshold.
- Does James N. Topper lead rounds?
- Yes — James N. Topper has led 10 tracked investments.